Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37713
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLeonardi, S-
dc.contributor.authorBranca, M-
dc.contributor.authorFranzone, A-
dc.contributor.authorMcFadden, E-
dc.contributor.authorPiccolo, R-
dc.contributor.authorJuni, P-
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorSteg, PG-
dc.contributor.authorSerruys, PW-
dc.contributor.authorBenit, E-
dc.contributor.authorLiebetrau, C-
dc.contributor.authorJanssens, L-
dc.contributor.authorFerrario, M-
dc.contributor.authorZurakowski, A-
dc.contributor.authorDiletti, R-
dc.contributor.authorDominici, M-
dc.contributor.authorHuber, K-
dc.contributor.authorSlagboom, T-
dc.contributor.authorBuszman, P-
dc.contributor.authorBolognese, L-
dc.contributor.authorTumscitz, C-
dc.contributor.authorBryniarski, K-
dc.contributor.authorAminian , A-
dc.contributor.authorVROLIX, Mathias-
dc.contributor.authorPetrov, I-
dc.contributor.authorGarg, S-
dc.contributor.authorNaber, C-
dc.contributor.authorProkopczuk, J-
dc.contributor.authorHamm, C-
dc.contributor.authorHeg, D-
dc.contributor.authorWindecker, S-
dc.contributor.authorValgimigli, M-
dc.date.accessioned2022-07-13T10:14:47Z-
dc.date.available2022-07-13T10:14:47Z-
dc.date.issued2021-
dc.date.submitted2022-07-06T14:22:54Z-
dc.identifier.citationCirculation-Cardiovascular Quality and Outcomes, 14 (2) , p. 144 -151-
dc.identifier.urihttp://hdl.handle.net/1942/37713-
dc.description.abstractBACKGROUND: Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events.METHODS: We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers.RESULTS: Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR-reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65-0.74) and 0.54 (95% CI, 0.45-0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75-0.79) and 0.71 (95% CI, 0.68-0.74) for bleeding; 0.70 (95% CI, 0.62-0.79) and 0.59 (95% CI, 0.43-0.74) for stroke; 0.59 (95% CI, 0.52-0.66) and 0.39 (95% CI, 0.25-0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak.CONCLUSIONS: Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03231059.-
dc.description.sponsorshipDr Leonardi reports grants and personal fees from AstraZeneca and personal fees from Bayer, BMS/PFIZER, and CHIESI, outside the submitted work. Dr McFadden reports personal fees and nonfinancial support from the University of Bern and Daiichi Sankyo Europe and other from AstraZeneca and Menarini Ireland, outside the submitted work. Dr Jüni serves as an unpaid member of the steering group of trials funded by AstraZeneca, Biotronik, Biosensors, St. Jude Medical, and The Medicines Company; has received research grants to the institution from AstraZeneca, Biotronik, Biosensors International, Eli Lilly, and The Medicines Company; and reports honoraria to the institution for participation in advisory boards and consulting from Amgen, Ava, and Fresenius but has not received personal payments by any pharmaceutical company or device manufacturer. Dr Vranckx reports personal fees from AstraZeneca during the conduct of the study and personal fees from Daiichi Sankyo, Bayer AG, and CSL Behring, outside the submitted work. Dr Steg reports grants from Bayer/Janssen; grants and personal fees from Merck, Sanofi, Servier, and Amarin; and personal fees from Amgen, Bayer/Janssen, Bristol-Myers Squibb, Idorsia, Boehringer Ingelheim, Pfizer, Novartis, Regeneron, Eli Lilly, NovoNordisk, and AstraZeneca, outside the submitted work. Dr Serruys reports personal fees and other from Abbott, Biosensor, Cardialysis, Medtronic, Sino Medical Sciences, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. Dr Diletti reports grants from AstraZeneca, outside the submitted work. Dr Naber reports personal fees from Abbott, Biosensors, Biotronik, and Medtronic, outside the submitted work. Dr Windecker reports grants from Amgen, Abbott, BMS, Boston Scientific, CSL Behring, Bayer, Biotronik, Medtronic, Edwards Lifesciences, Polares, and Sinomed, outside the submitted work. Dr Valgimigli reports grants from Abbott and Medicure; grants and personal fees from AstraZeneca and Terumo; and personal fees from Chiesi, Bayer, Daiichi-Sankyo, Amgen, Alvimedica, Biosensors, and Idorsia, outside the submitted work.-
dc.language.isoen-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.rights2021 American Heart Association, Inc.-
dc.subject.otherbenchmarking-
dc.subject.otherfeasibility studies-
dc.subject.otherhemorrhage-
dc.subject.othermyocardial infarction-
dc.subject.otherthrombosis-
dc.titleComparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY-
dc.typeJournal Contribution-
dc.identifier.epage151-
dc.identifier.issue2-
dc.identifier.spage144-
dc.identifier.volume14-
local.bibliographicCitation.jcatA1-
local.publisher.placeTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1161/circoutcomes.120.006581-
dc.identifier.pmid33535773-
dc.identifier.isi000639301400001-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.accessRightsOpen Access-
item.fullcitationLeonardi, S; Branca, M; Franzone, A; McFadden, E; Piccolo, R; Juni, P; VRANCKX, Pascal; Steg, PG; Serruys, PW; Benit, E; Liebetrau, C; Janssens, L; Ferrario, M; Zurakowski, A; Diletti, R; Dominici, M; Huber, K; Slagboom, T; Buszman, P; Bolognese, L; Tumscitz, C; Bryniarski, K; Aminian , A; VROLIX, Mathias; Petrov, I; Garg, S; Naber, C; Prokopczuk, J; Hamm, C; Heg, D; Windecker, S & Valgimigli, M (2021) Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. In: Circulation-Cardiovascular Quality and Outcomes, 14 (2) , p. 144 -151.-
item.fulltextWith Fulltext-
item.contributorLeonardi, S-
item.contributorBranca, M-
item.contributorFranzone, A-
item.contributorMcFadden, E-
item.contributorPiccolo, R-
item.contributorJuni, P-
item.contributorVRANCKX, Pascal-
item.contributorSteg, PG-
item.contributorSerruys, PW-
item.contributorBenit, E-
item.contributorLiebetrau, C-
item.contributorJanssens, L-
item.contributorFerrario, M-
item.contributorZurakowski, A-
item.contributorDiletti, R-
item.contributorDominici, M-
item.contributorHuber, K-
item.contributorSlagboom, T-
item.contributorBuszman, P-
item.contributorBolognese, L-
item.contributorTumscitz, C-
item.contributorBryniarski, K-
item.contributorAminian , A-
item.contributorVROLIX, Mathias-
item.contributorPetrov, I-
item.contributorGarg, S-
item.contributorNaber, C-
item.contributorProkopczuk, J-
item.contributorHamm, C-
item.contributorHeg, D-
item.contributorWindecker, S-
item.contributorValgimigli, M-
crisitem.journal.issn1941-7705-
crisitem.journal.eissn1941-7713-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY.pdfPublished version378.85 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

10
checked on Apr 22, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.